Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Three lots of the investigational Fluzone vaccine with the 2008/2009 Northern Hemisphere
formulation will be administered intradermally (ID) using the Becton Dickinson Micro
Injection System.

Inclusion Criteria :

- Aged 18 to 64 years on the day of vaccination.

- Informed consent form signed and dated.

- Able to attend all scheduled visits and to comply with all trial procedures.

- For women of child bearing potential, avoid becoming pregnant (use of an effective
method of contraception or abstinence) for at least 4 weeks prior to vaccination,
until at least 4 weeks after vaccination.

Exclusion Criteria :

- Known systemic hypersensitivity to any of the vaccine components or history of a
life-threatening reaction to the trial vaccine or to a vaccine containing any of the
same substances.

- For a woman of child-bearing potential: known pregnancy or positive serum/urine
pregnancy test.

- Breast-feeding woman.

- Participation in another clinical trial investigating a vaccine, drug, medical
device, or a medical procedure in the four weeks preceding the trial vaccination.

- Planned participation in another clinical trial during the present trial period.

- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
or long-term systemic corticosteroids therapy

- Chronic illness, at a stage that could interfere with trial conduct or completion, in
the opinion of the investigator.

- Current alcohol abuse or drug addiction that may interfere with the subject's ability
to comply with trial procedures.

- Receipt of blood or blood-derived products in the past 3 months that might interfere
with the assessment of immune response.

- Receipt of any vaccination in the 4 weeks preceding the trial vaccination.

- Planned receipt of any vaccine in the 4 weeks following the trial vaccination.

- Previous vaccination against influenza in the past 6 months with the trial vaccine or
another vaccine.

- Thrombocytopenia or bleeding disorder in the 3 weeks preceding inclusion.

- Subject deprived of freedom by an administrative or court order, or in an emergency
setting, or hospitalized without his/her consent.

- Neoplastic disease or any hematologic malignancy, (except localized skin or prostate
cancer that is stable at the time of vaccination in the absence of therapy, and
subjects who have a history of neoplastic disease and who have been disease free for
>=5 years).

- Personal or family history of Guillain-Barré Syndrome.